CRIS - .94 Pre-market 1.15/1.16 Curis Announced TakeAim Lymphoma Data Presented at ASCO for the Combination of Emavusertib Plus Ibrutinib Show Tumor Reduction in 8 of 9 Evaluable Patients, Including 2 Complete Responses and 2 Partial Responses https://stockcharts.com/h-sc/ui?s=cris